ArticlePloS one2013
Apolipoprotein a-I is a potential mediator of remote ischemic preconditioning.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Protective Effect of Remote Ischemic Preconditioning against Myocardial Ischemia-Reperfusion Injury in Rats and Mice: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2022Pooled it
- Trial
- Nephroprotective effect of remote ischemic conditioning on type 2 diabetic rats.Iranian journal of basic medical sciences · 2024Article
- Transcriptome analysis reveals ADAMTS15 is a potential inflammation-related gene in remote ischemic postconditioning.Frontiers in cardiovascular medicine · 2023Article
- HIF-1α mediates the protective effect of plasma extracellular particles induced by remote ischaemic preconditioning on oxidative stress injury in human umbilical vein endothelial cells.Experimental and therapeutic medicine · 2022Article
- Immune Modulation as a Key Mechanism for the Protective Effects of Remote Ischemic Conditioning After Stroke.Frontiers in neurology · 2021Review
- Perioperative Cardioprotection by Remote Ischemic Conditioning.International journal of molecular sciences · 2019Review
- Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection.Oncotarget · 2019Review
- Neural mechanisms in remote ischaemic conditioning in the heart and brain: mechanistic and translational aspects.Basic research in cardiology · 2018Review
- Correction to: Neuroimmune Response in Ischemic Preconditioning.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Article
- Remote ischemic preconditioning fails to reduce infarct size in the Zucker fatty rat model of type-2 diabetes: role of defective humoral communication.Basic research in cardiology · 2018Article
- Lung protection in patients undergoing pulmonary lobectomy: a new perspective for remote ischemic conditioning in surgery?Journal of thoracic disease · 2018Article
- Mitochondrial dynamics and preconditioning in white matter.Conditioning medicine · 2018Article
- Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization.Scientific reports · 2017Article
- Review
- Cardioprotection by remote ischemic conditioning and its signal transduction.Pflugers Archiv : European journal of physiology · 2017Review
- Remote ischemic preconditioning triggers changes in autonomic nervous system activity: implications for cardioprotection.Physiological reports · 2017Article
- Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning.Cardiovascular research · 2016Article
- Neuroimmune Response in Ischemic Preconditioning.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
- Metabolic Signature of Remote Ischemic Preconditioning Involving a Cocktail of Amino Acids and Biogenic Amines.Journal of the American Heart Association · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRemote ischemic preconditioning (RIPC) has emerged as an attractive strategy in clinical settings. Despite convincing evidence of the critical role played by circulating humoral mediators, their actual identities remain unknown. In this study, we aimed to identify RIPC-induced humoral mediators using a proteomic approach.
methodsand Results Rats were exposed to 10-min limb ischemia followed by 5- (RIPC 5') or 10-min (RIPC 10') reperfusion prior to blood sampling. The control group only underwent blood sampling. Plasma samples were analyzed using surface-enhanced laser desorption and ionization - time of flight - mass spectrometry (SELDI-TOF-MS). Three protein peaks were selected for their significant increase in RIPC 10'. They were identified and confirmed as apolipoprotein A-I (ApoA-I). Additional rats were exposed to myocardial ischemia-reperfusion (I/R) and assigned to one of the following groups RIPC+myocardial infarction (MI) (10-min limb ischemia followed by 10-min reperfusion initiated 20 minutes prior to myocardial I/R), ApoA-I+MI (10 mg/kg ApoA-I injection 10 minutes before myocardial I/R), and MI (no further intervention). In comparison with untreated MI rats, RIPC reduced infarct size (52.2±3.7% in RIPC+MI vs. 64.9±2.6% in MI; p<0.05). Similarly, ApoA-I injection decreased infarct size (50.9±3.8%; p<0.05 vs. MI).
conclusionsRIPC was associated with a plasmatic increase in ApoA-I. Furthermore, ApoA-I injection before myocardial I/R recapitulated the cardioprotection offered by RIPC in rats. This data suggests that ApoA-I may be a protective blood-borne factor involved in the RIPC mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.